119 related articles for article (PubMed ID: 3499544)
21. Stimulation of B-chronic lymphocytic leukemia populations by recombinant interleukin-4 and other defined growth-promoting agents.
Ghaderi AA; Richardson P; Cardona C; Millsum MJ; Ling N; Gillis S; Ledbetter J; Gordon J
Leukemia; 1988 Mar; 2(3):165-70. PubMed ID: 3126369
[TBL] [Abstract][Full Text] [Related]
22. B5, a new B cell-restricted activation antigen.
Freedman AS; Boyd AW; Anderson KC; Fisher DC; Schlossman SF; Nadler LM
J Immunol; 1985 Apr; 134(4):2228-35. PubMed ID: 2579134
[TBL] [Abstract][Full Text] [Related]
23. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
[TBL] [Abstract][Full Text] [Related]
24. Differentiation of purified malignant B cells induced by PMA or by activated normal T cells.
van Kooten C; Rensink I; Aarden L; van Oers R
Leukemia; 1993 Oct; 7(10):1576-84. PubMed ID: 8105156
[TBL] [Abstract][Full Text] [Related]
25. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.
Tedder TF; Boyd AW; Freedman AS; Nadler LM; Schlossman SF
J Immunol; 1985 Aug; 135(2):973-9. PubMed ID: 3925015
[TBL] [Abstract][Full Text] [Related]
26. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).
Ledbetter JA; Shu G; Gallagher M; Clark EA
J Immunol; 1987 Feb; 138(3):788-94. PubMed ID: 3492534
[TBL] [Abstract][Full Text] [Related]
27. Functional interaction between B cell subpopulations defined by CD23 expression.
Armitage RJ; Goff LK
Eur J Immunol; 1988 Nov; 18(11):1753-60. PubMed ID: 2974422
[TBL] [Abstract][Full Text] [Related]
28. The Fc epsilon R2/CD23 antigen: a hallmark of chronic lymphocytic leukemia B cells.
Almerigogna F; Biagiotti R; Giudizi MG; Alessi A; Ricci M; Bosi A; Romagnani S
Ric Clin Lab; 1989; 19(2):129-38. PubMed ID: 2528201
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays.
Clutterbuck E; Shields JG; Gordon J; Smith SH; Boyd A; Callard RE; Campbell HD; Young IG; Sanderson CJ
Eur J Immunol; 1987 Dec; 17(12):1743-50. PubMed ID: 3500861
[TBL] [Abstract][Full Text] [Related]
30. Functional studies examining the subpopulation of human B lymphocytes responding to high molecular weight B cell growth factor.
Ambrus JL; Chesky L; Stephany D; McFarland P; Mostowski H; Fauci AS
J Immunol; 1990 Dec; 145(12):3949-55. PubMed ID: 2258603
[TBL] [Abstract][Full Text] [Related]
31. Role of recombinant interleukin-1 compared to recombinant T-cell replacing factor/interleukin-5 in B-cell differentiation.
Koyama N; Harada N; Takahashi T; Mita S; Okamura H; Tominaga A; Takatsu K
Immunology; 1988 Feb; 63(2):277-83. PubMed ID: 3280472
[TBL] [Abstract][Full Text] [Related]
32. Molecular control of B lymphocyte growth and differentiation.
Banchereau J; Brière F; Liu YJ; Rousset F
Stem Cells; 1994 May; 12(3):278-88. PubMed ID: 7521239
[TBL] [Abstract][Full Text] [Related]
33. Demonstration that human B cells respond differently to interleukin 2 and B cell differentiation factor based on their stages of maturation.
Nakagawa T; Nakagawa N; Goldstein H; Volkman DJ; Fauci AS
J Immunol; 1986 Nov; 137(10):3175-82. PubMed ID: 2945860
[TBL] [Abstract][Full Text] [Related]
34. Identification of two distinct CD5- B cell subsets from human tonsils with different responses to CD40 monoclonal antibody.
Dono M; Zupo S; Masante R; Taborelli G; Chiorazzi N; Ferrarini M
Eur J Immunol; 1993 Apr; 23(4):873-81. PubMed ID: 7681401
[TBL] [Abstract][Full Text] [Related]
35. A human CD4- T cell leukemia subclone with contact-dependent helper function.
Yellin MJ; Lee JJ; Chess L; Lederman S
J Immunol; 1991 Nov; 147(10):3389-95. PubMed ID: 1834738
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies reactive with hairy cell leukemia.
Visser L; Shaw A; Slupsky J; Vos H; Poppema S
Blood; 1989 Jul; 74(1):320-5. PubMed ID: 2665837
[TBL] [Abstract][Full Text] [Related]
37. Synergy of B cell growth factor and interleukin 2 in the proliferation of activated human B cells.
Romagnani S; Giudizi GM; Maggi E; Almerigogna F; Biagiotti R; Del Prete G; Mazzetti M; Alessi A; Vercelli D; Ricci M
Eur J Immunol; 1985 Dec; 15(12):1158-64. PubMed ID: 3936718
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibody against a membrane antigen characterizing leukemic human B-lymphocytes.
Forster HK; Gudat FG; Girard MF; Albrecht R; Schmidt J; Ludwig C; Obrecht JP
Cancer Res; 1982 May; 42(5):1927-34. PubMed ID: 6175400
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
40. Soluble, but not immobilized, anti-IgM antibody inhibits post-activation events leading to T-cell-dependent B-cell differentiation.
Zamorano J; Rivas D; Gayo A; Mozo L; Gutiérrez C
Immunology; 1995 Jun; 85(2):241-7. PubMed ID: 7642212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
